Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amprenavir + abacavir + lamivudine + zidovudine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a four-drug combination of amprenavir, abacavir, lamivudine, and zidovudine, each of which is an antiretroviral used in the treatment of HIV-1 infection. Amprenavir is a protease inhibitor, while abacavir, lamivudine, and zidovudine are nucleoside analogue reverse transcriptase inhibitors (NRTIs). The combination targets viral replication through inhibition of both the HIV-1 reverse transcriptase enzyme (by the NRTIs) and the HIV-1 protease enzyme (by amprenavir). This regimen has been evaluated in phase II/III studies, showing potent viral suppression and increases in CD4+ cell counts in both treatment-naive and experienced HIV-1 infected patients. The combination is generally taken orally and is intended to provide potent multi-mechanistic antiretroviral therapy[5][9].
- Other names
- amprenavir + abacavir + lamivudine + zidovudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)
Beyond the preview
Go deeper on amprenavir + abacavir + lamivudine + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amprenavir + abacavir + lamivudine + zidovudine.